GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeNeuro SA (XPAR:GNRO) » Definitions » 5-Year Sharpe Ratio

GeNeuro (XPAR:GNRO) 5-Year Sharpe Ratio : -0.12 (As of Jul. 02, 2025)


View and export this data going back to 2016. Start your Free Trial

What is GeNeuro 5-Year Sharpe Ratio?

The 5-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past five years. As of today (2025-07-02), GeNeuro's 5-Year Sharpe Ratio is -0.12.


Competitive Comparison of GeNeuro's 5-Year Sharpe Ratio

For the Biotechnology subindustry, GeNeuro's 5-Year Sharpe Ratio, along with its competitors' market caps and 5-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GeNeuro's 5-Year Sharpe Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GeNeuro's 5-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where GeNeuro's 5-Year Sharpe Ratio falls into.


;
;

GeNeuro 5-Year Sharpe Ratio Calculation

The 5-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last five years. A stock / portfolio's 5-Year Sharpe Ratio can be calculated by dividing the difference between the five-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past five years.


GeNeuro  (XPAR:GNRO) 5-Year Sharpe Ratio Explanation

The 5-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past five years. It is calculated as the annualized result of the average five-year monthly excess returns divided by its standard deviation in the five-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


GeNeuro 5-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of GeNeuro's 5-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GeNeuro Business Description

Traded in Other Exchanges
N/A
Address
3 chemin du Pre-Fleur, Plan-les-Ouates, Geneva, CHE, 1228
GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).

GeNeuro Headlines

No Headlines